Next Phase Newsletter

A corporate venture arm of a leading global Contract Research, Development and Manufacturing Organization (CRDMO) founded in 2018 is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The venture arm does not lead rounds and prefers companies with a lead investor in place. Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The venture arm makes equity investments only and does not have an equity-for-service model. 
 
Separately from the corporate venture arm, the organizations runs a program that collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the organization’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 

The venture arm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 

The venture arm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

The venture’s team is open to meeting with companies in their initial stage of fundraising and will track their progress. But they will only look deeper into the opportunities when a lead investor is in play and the company is close to signing a term sheet.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture fund founded in 2019 with headquarters in the Bay Area, an $100M AUM, and a current fund size of $50M USD, is dedicated towards medical device-centered technologies from Series A to C. The firm is open to earlier-stage opportunities if the project aligns with the firm’s interests. The typical initial check size is $1-5M, and the firm plans to make 4-5 investments in the next year. The firm invests globally with a focus in the United States. 

The firm invests in PMA and 510K medical devices, specifically those pertaining to surgical innovation, in development and clinical phases. The firm does not invest in heath information systems or wearables. Otherwise, the firm considers device-approached technologies in the therapeutics, diagnostics, and digital health space in development and clinical phases. While the firm is open to all indications, cardiology, neurology, and surgery are areas of interest. 

The firm does not have any requirements of the management team. The firm will both lead and co-lead depending on the area of expertise. Board seating will be required when leading investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture arm of an innovation hub headquartered in California for life science, medtech, and technology companies invests in Pre-Seed and Seed stage biotech, device, and ag-tech companies in the U.S. The firm acts as a lead investor. For Pre-Seed rounds, typical check size falls between $250k-1M and for Seed rounds, typical check size falls between $1M-3M. For their main fund, it is not required for companies to go through the accelerator program, however the resources are available and encouraged 

In terms of life sciences and healthcare, the firm is interested in biotech and medical devices. For biotech, the firm is subsector agnostic, including drug development and bio tools, for device, the firm is open to all classes. The firm is also indication-agnostic. The firm typically looks at companies in pre-clinical stages. 

The firm requires companies to already be incorporated and have their CEOs to be fulltime. The firm may take a board seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A manufacturing company has a wide range of businesses including analytical instruments, medical devices, and industrial equipment. Recently, the company has been focusing on healthcare, specifically in clinical diagnostics and biomanufacturing. In April 2023, the company established a CVC (corporate venture capital) department and is looking for strategic partnerships with companies with cutting-edge technology that align with their businesses. The fund will be managed for 10 years with a total investment of $50M USD. So far, the venture arm has invested in 3 companies in the U.S. and Japan and is looking to expand their investments in the States, though they are open to meeting with global companies. The fund is looking to invest in Pre-Seed to Early rounds but may invest as far as Series A. Typical check size can range from $1-10M USD but can exceed if there is a particularly strong interest in a technology. 

In terms of healthcare, the venture arm is looking to invest in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but consumables as well.  

To attract investment from the venture arm, having a lead investor is desirable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A VC fund based in the U.S. invests in early-stage applied AI companies in healthcare, enterprise, and automation. The firm follows their thesis of partnering and investing in entrepreneurs who have a deep desire to use AI-enabled technology to tackle the most challenging problems in the given industries. The founder, a tech entrepreneur themself, started the fund with the idea of wanting to pay it forward towards startups that can make a large impact in the world. The firm can invest in Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K. The firm can lead investments as they like to be active investors, utilizing their strong network to help companies with operations, funding, commercialization, and more. 

In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics, and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets. 

The firm prefers to take a board seat however, it is not required. 

 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A private investment group in South Carolina invests in two verticals, healthcare and advanced computing. The firm primarily invests in medical devices (60%), as well as diagnostics (20%), life science tools (10%), and AI-based drug discovery platforms (10%). The firm invests in seed-Series A, investing between $1-5M in companies that have a validated prototype and have a defined regulatory path. The firm invests primarily in US-based companies but will invest in Israel and Europe.

The firm invests primarily in medical devices, with some investments in diagnostics as well. In terms of medical devices, the firm will invest in class II and class III devices, investing either just before, during or after FDA approval for class II devices, and in devices that have received IDE approval for class III devices. For AI-based companies, the firm is interested in technologies such as drug discovery. 

The firm can lead, co-invest or act as the sole investor. The firm takes a board seat with any company in which they invest. The firm will only invest in companies with validated prototypes and will not invest pre-company formation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A Norway-based coalition that partners between public, private, philanthropic, and civil organizations is currently investing in new platform technologies for rapid vaccine research and development and other interventions for pandemics and endemics. The organization is currently investing from their current 5-year plan. The organization is stage agnostic with typical check size being flexible but ranging from $1-100M USD. The organization is open to any geographic regions but is looking to invest in the global south in particular. Investments are typically made through non-dilutive funding but can explore other funding opportunities including equity. 

The organization invests in the infectious disease space whether that be vaccines, MABs, or other pandemic-preventing interventions; generally speaking, biotech companies in pandemic-related indications. It is unlikely that the organization would look at diagnostics, devices or digital health unless there was a very specific pandemic-preparedness value proposition. The organization is stage-agnostic and will typically meet with companies from pre-clinical stages to Phase II.  

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.